

# **Dabur India**

67.88

7.03

17.76

7.33

0.00

67.90

6.67

18.21

7.22

0.00

# More than just a 'rural play'

We attended the analyst meet of Dabur India. We observed that Dabur's strategy has turned aggressive (outperform market) vs. defensive (riding with the tide). Dabur headed by Mohit Malhotra (new CEO, joined Aug'18) is shaping up well. Mohit is taking the right steps which were required years ago. Dabur has always been admired due to its wide product range and strong rural play (45% rev mix). However, the co was performing below its potential. Extensive product range was limiting management's focus (defensive approach due to focus on many brands). Rural play (acceleration) has been more of a hope than a reality due to competition from regional players and entry of large players in upcountry markets. With the change in approach, we are confident that Dabur can outperform over the next 3-5 years. Current slowdown might impact near term performance but we expect a mean reversion for many brands over the next few years. We see a re-rating potential in Dabur. We are upgrading the target multiple to 40x (38x earlier) on Sep-21 EPS. Our TP for Dabur is Rs 497. Maintain BUY.

- Implementing tried and tested strategies: Management is now focusing on implementing the wining strategies i.e. "Strengthening the core business". We have seen a turnaround in performances with a change in approach like HUL (Sanjiv Mehta -2013), Britannia (Varun Berry - 2013), Nestle (Suresh Narayanan - 2015) and Jubilant FoodWorks (Pratik Pota -2017).
- Dabur's key thrust areas: Dabur has several brands that are under indexed despite being popular for years. Focus is on 8 power brands (~65% rev mix) which are supported by concentrated media spends. Co is accelerating product innovation and brand renovation

- which will ensure scalability of under indexed brands. Dabur's 5 strategies are (1) Scaling power brands, (2) Driving innovation and renovation for market leadership, (3) Distribution expansion, (4) Operational excellence and (5) Capability improvement.
- **Strengthening distribution:** Dabur has aggressive plans to deepen its direct reach in rural markets (45% rev mix). In 1QFY20, co added 4k villages which led to outperformance in volume growth. Dabur has plans to reach 55/65k villages in FY20/21 vs 44k in FY19. Post GST, most of the players are ramping up their direct reach which will support new launches and diversify from wholesale channel.
- Stance: Co level initiatives are on track. We will be keen to see how Mohit will drive Dabur's large but under indexed portfolio. Revitalizing the strategy should fill the gaps in product/distribution/ communication. There are few low hanging fruits which Mohit will try to assess initially, resulting in a quick turnaround in performance. Rural tilt in sales mix means progress of monsoon (normal) and government initiatives are key (wage growth is muted). Our change in rating is based on medium term performance.

#### Financial Summary (Consolidated)

(Rs mn)	FY18	FY19	FY20E	FY21E	FY22E
Net Sales	77,219	85,331	93,937	105,638	118,834
EBITDA	16,174	17,396	20,311	23,530	27,060
APAT	13,663	14,436	16,908	20,348	23,540
EPS (Rs)	7.76	8.20	9.57	11.52	13.32
P/E (x)	57.2	54.2	46.4	38.6	33.3
EV / EBITDA (x)	46.8	43.5	37.2	31.8	27.5
RoIC	47.3	50.1	53.1	59.0	65.6

Source: Company, HDFC sec Inst Research

INDUSTRY			FMCG		
CMP (as on 09	Sep 2019	)	Rs 444		
<b>Target Price</b>	Target Price				
Nifty			11,003		
Sensex			37,145		
KEY STOCK DATA	Α				
Bloomberg		DA	ABUR IN		
No. of Shares (m	No. of Shares (mn)				
MCap (Rs bn) / (	\$ mn)	785	785/10,947		
6m avg traded v	alue (Rs m	n)	1,034		
STOCK PERFORM	MANCE (%)	)			
52 Week high /	low	Rs 4	77/357		
	3M	6M	12M		
Absolute (%)	9.9	2.8	(5.1)		
Relative (%)	1.5	(1.9)			
SHAREHOLDING	PATTERN	(%)			
	Mar-	19	Jun-19		

#### Naveen Trivedi

**Promoters** 

**FPIs** 

FIs & Local MFs

Public & Others

Pledged Shares

Source: BSE

naveen.trivedi@hdfcsec.com +91-22-6171-7324

#### Siddhant Chhabria

siddhant.chhabria@hdfcsec.com +91-22-6171-7336



Power brands grew by ~15% in FY19 vs. ~9% growth in expower brands.

Power brands have outperformed domestic biz on a 3 year CAGR basis

Vatika (Rs 2.5bn) is the 9th brand Dabur has identified under power brands


# **Business Strategy**

- (1) Power Brands Strategy
- (2) Driving Innovation and Renovation
- (3) Distribution Expansion
- (4) Operational Excellence
- (5) Capability Enhancement

#### (1) Power brands strategy

- Focus on 8 brands: Dabur is putting their weight behind 8 brands to drive overall growth. These 8 brands (65% revenue mix) are either present in a large category (gain market share) or in an under-penetrated category (grow the category). We admire Dabur's strategy of focusing on limited brands rather than investing limited funds behind each brand.
- Concentrated A&P Spends: Dabur has rationalised its A&P spends in the last few years (7.1% of sales in FY19 vs. 9.8% in FY16). During this period, the co has shifted funds to ATL from BTL. Mohit's strategy on A&P is to increase spend on power brands (~20%) and continue to rationalise overall spend (growing at 5-6%). Most of the power brands are present in under-penetrated categories and hence higher A&P spends would support in growing the category.

#### Power Brands Revenue Growth - FY19





Chyawanprash and Honey have regained share post Patanjali's fallout

Dabur honey's share dropped to 40% in FY18 (vs. peak of 60%). It has since recovered to >50%.

In Chyawanprash, Dabur's share, which had dropped to 58% in FY17, has returned to over 60% now.

Dabur has gained 300-400bps market share in Lal Tail in FY19

Honitus addressable market stands at Rs 3bn

North contributes 70% of Dabur Real's mix. In few pockets in North, Real has a share of >70% (vs. 59.5% share in India). Juice market is witnessing severe competition from dairy based beverages.

## Power Brands – Addressable market is ~6x

Power Brands	Category	Mkt Size (Rs bn)	Mkt Share	Rev FY19 (Rs bn)	Dom. Rev Mix FY19	Brand Specific Strategy
Chyawanprash	Health Supplements	9.0	60%	4.8	13%	<ul> <li>Focus on region specific products and variants.</li> <li>Enhance distribution (chemist) and drive consumer frequency across seasons (70% consumption in winters)</li> </ul>
Honey	Health Supplements	10.0	50%	5.0	13%	<ul> <li>Market share has recovered after the fall-out of Patanjali</li> <li>Launching premium variants</li> <li>Strengthen fitness proposition</li> <li>Increase consumer frequency via targeted campaigns</li> </ul>
Lal Tail	отс	3.5	35%	1.3	3%	- Extend brand beyond massage oil (baby care portfolio) - Distribution enhancement
Honitus	ОТС	20.0	3%	0.6	2%	<ul><li>Introduce more formats</li><li>Regionalization</li><li>New formats &amp; variants (lozenges, hot sip)</li><li>Distribution enhancement</li></ul>
Pudin Hara	Digestives	4.0	20%	0.8	2%	<ul> <li>Scale &gt;Rs 1bn in 3-4 years.</li> <li>Leverage brand equity to other premium segments (food)</li> <li>More formats (powder sachets)</li> <li>Scale distribution</li> </ul>
Red paste	Oral Care	80.0	~10%	7.2	19%	<ul> <li>Naturals segment in oral care is now growing at 15% (3-4x category growth)</li> <li>Dabur believes naturals share in oral care can scale to 40-50% vs. 25% currently</li> </ul>
Amla Franchise	Hair Oil	71.5	11%	8.0	21%	<ul> <li>Strengthen the core (Dabur Amla)</li> <li>Premiumization</li> <li>Scale flanker brands (Brahmi &amp; Sarson Amla)</li> <li>Improve distribution</li> </ul>
Real	F&B	18.0	56%	10.0	27%	<ul> <li>Drive consumer frequency</li> <li>Expansion in low through put geographies</li> <li>Premiumization via new health-based variants</li> <li>Entering fruit drinks segment</li> </ul>
Total	Pov	216.0	17%	37.7	100%	Dower Prends account for WCTO/ of demostic revenue
Dabur Domestic	Rev.			59.1	64%	- Power Brands account for ~65% of domestic revenues

Source: HDFC sec Inst Research



# We are encouraged by the change in communication for brands like:

- (1) Chywanprash- "All season product"
- (2) Honey "Fitness friendly" and "Tasty product to replace Jam"
- (3) Amla Hair Oil To beat marginal players by saying "Asli Amla Dabur Amla"
- (4) Pudin Hara "Keep the body cool (Thanda Theme)" and "Best medicine for acidity"
- (5) Lal Tel "Sticky oil but makes the baby stronger"

#### (2) Driving Innovation and renovation

Several disruptions in the last 2-3 years led to muted new launches. Easing competitive intensity and normalized channels have improved the environment for new launches. Dabur's focus on innovation will be around its power brands. NPD share for Dabur is at 2% and is expected to grow to 3-4% (lower guidance vs. peers) in the next few years. However, near term slowdown will act as a hindrance to scale new launches.

#### **New Launches and Re-launches**





Dabur plans to reach 65k villages directly by FY21 (vs. 44k in FY19).

In addition to increasing penetration, co has launched LUPs (<Rs 10 packs) in the home, personal care, food and healthcare range.

For eg. Pudin Hara is now available in a Rs 5 sachet and Dabur Red is available in a Rs 10 pack

In urban, Dabur's focus is on strengthening its position in modern trade (lower share vs. other channels).

### (3) Distribution Expansion

• After being impacted by GST implementation (wholesale disrupted), Dabur has increased its focus on distribution primarily in rural areas. Dabur aims to increase direct reach to 1.2mn outlets vs. 1.1mn in FY19. In urban, E-commerce and MT (combined contribute ~15% of domestic revenue) are already growing faster than GT. Dabur is increasing its direct reach in rural (55k villages in FY20E vs. 44k in FY19) to drive penetration and success of new launches.

#### **Channel Focus Strategy**





#### (4) Operational Excellence

• Dabur is driving several initiatives for cost optimisation and lead time to reduce its working capital requirement. 'Project Lakshya' is improving service levels (to distribution), reducing logistics cost and driving lower inventory levels. Consistent efforts have already brought down inventory levels at the channel level.

#### **Channel Focus Strategy**





### (5) Capability Enhancement

 Dabur's focus area is not only for the external but also improvising internal capabilities. In FY19, Dabur has increased its R&D spend by 16% to drive innovation. Co has also strengthened its presence in the ayurveda network to drive category growth.

#### **Enhancing capability in Ayurveda**

## Portfolio Expansion

- Classical & Branded Range enhancement
- Hridayasava, Pure Herb Churnas, Vasant Meha Ras, Glycodab



#### Increase Doctor Advocacy

- Increase Ayurvedic Doctor Coverage from 40,000 to 55,000
- Scientific Knowledge Dissemination – 50 Top Ayurvedic Colleges



#### Enhance Consumer Touch Points

- Increase Dabur Ayurved Chikitsalayas from 525 to 650
- Increase Dabur branded Ayurvedic Stores from 1,500 to 2,500

#### Consumer Engagement

- Health Camps
  - > 6,000 in Clinics
  - > 10 Lakh Rural Consumers
- Consumer Sampling through religious events







#### **Assumptions**

Particulars	FY18	FY19	FY20E	FY21E	FY22E
Domestic Gr. (%)	5.2	11.2	10.2	12.5	12.9
Hair Care Gr. (%)	4.2	13.8	10.6	12.0	10.0
Oral Care Gr. (%)	16.9	9.7	2.0	12.0	12.0
Health Supplements Gr. (%)	10.3	14.8	11.8	14.0	15.0
OTC & Ethicals Gr. (%)	5.2	14.1	11.0	14.0	15.0
Digestive Gr. (%)	10.4	16.6	9.2	12.0	14.0
Home Care Gr. (%)	14.2	13.0	10.7	14.0	14.0
Skin Care Gr. (%)	11.1	17.4	7.5	14.0	14.0
Foods Gr. (%)	1.5	9.3	2.5	13.5	13.0
International Gr. (%)	(6.3)	6.6	6.9	12.0	11.0
Consolidated Revenue Gr. (%)	6.9	10.5	10.1	12.5	12.5
Gross Margin (%)	50.5	49.5	50.2	50.6	50.7
ASP (% of sales)	7.9	7.1	7.2	7.1	7.0
Distribution (% of sales)	2.5	2.6	2.6	2.6	2.6
Employee (% of sales)	10.3	11.0	10.8	10.6	10.4
Other Expenses (% of sales)	9.0	8.4	8.1	8.1	7.9
EBITDA Margin (%)	20.9	20.4	21.2	22.3	22.8
Tax Rate (%)	19.8	16.2	20.0	20.0	20.0

Source: HDFC sec Inst Research

**Change in Estimate** 

	FY20E			FY21E			FY22E		
	New	Old	Change	New	Old	Change	New	Old	Change
Net Revenue	93,937	95,029	-1.1%	105,638	106,875	-1.2%	118,834	119,475	-0.5%
EBITDA	20,311	21,096	-3.7%	23,530	24,687	-4.7%	27,060	28,125	-3.8%
APAT	19,943	20,728	-3.8%	23,530	24,319	-3.2%	27,060	27,757	-2.5%
EPS	16,908	17,475	-3.2%	20,348	21,060	-3.4%	23,540	24,268	-3.0%

Source: HDFC sec Inst Research

We cut our estimates by ~3% to factor near-term slowdown and expect growth to accelerate in 2HFY20 which will be supported by favorable base



## **Peer Set Comparison**

	MCap CMP		. CIMP IP			P/E (x)		EV/EBITDA (x)		(x)	Core RoCE (%)					
Company	(Rs bn)	(Rs)	Reco.	(Rs)	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E
HUL	3,949	1,828	NEU	1,847	28.1	32.7	39.9	64.9	55.9	45.8	43.7	40.3	31.8	248.6	36.6	25.6
ITC	2,741	245	BUY	336	10.4	11.4	12.5	23.5	21.6	19.6	14.8	13.4	11.9	39.2	40.6	43.8
Nestle	1,238	12,840	NR	11,064	167.1	206.5	245.9	76.8	62.2	52.2	44.3	38.0	32.5	82.1	101.4	121.4
Dabur	782	444	BUY	497	8.2	9.6	11.5	54.2	46.4	38.6	43.5	37.2	31.8	50.1	53.1	59.0
Britannia	644	2,683	NEU	2,674	48.1	52.5	63.8	55.8	51.1	42.1	36.4	32.3	26.6	39.3	38.7	44.5
Marico	500	387	BUY	395	7.2	8.8	10.5	53.7	43.9	36.7	38.9	30.8	26.8	48.8	48.0	54.1
Colgate	342	1,256	NEU	1,281	27.6	30.8	35.5	45.6	40.8	35.4	27.3	24.4	21.4	67.2	70.6	78.4
Emami	137	294	BUY	464	11.0	13.0	15.0	26.7	22.6	19.6	18.0	15.6	13.5	21.5	27.0	33.0
Jub. Food	160	1,210	BUY	1,775	24.1	29.4	36.8	50.2	41.2	32.9	25.5	22.4	17.8	45.8	47.4	40.0
United Spirits	448	617	BUY	651	10.2	12.4	15.7	60.3	49.9	39.4	35.1	27.7	23.0	15.6	18.1	21.1
Radico Khaitan	40	300	BUY	492	14.1	15.8	18.9	21.2	19.0	15.9	12.3	10.9	9.2	11.5	12.2	13.5

Source: HDFC sec Inst Research

NR: Not Rated



#### **Income Statement**

(Rs mn)	FY18	FY19	FY20E	FY21E	FY22E
Net Revenues	77,219	85,331	93,937	105,638	118,834
Growth (%)	6.9	10.5	10.1	12.5	12.5
Material Expenses	38,199	43,090	46,763	52,169	58,598
Employee Expense	7,928	9,379	10,106	11,165	12,393
A&P Expense	6,067	6,083	6,769	7,483	8,306
Distribution Expense	1,914	2,201	2,423	2,724	3,065
Other Expenses	6,936	7,182	7,566	8,567	9,412
EBITDA	16,174	17,396	20,311	23,530	27,060
EBITDA Growth (%)	7.2	7.6	16.8	15.8	15.0
EBITDA Margin (%)	20.9	20.4	21.6	22.3	22.8
Adj EBITDA (IND-AS 116)	16,174	17,396	19,943	23,530	27,060
Adj EBITDA Growth (%)	7.2	7.6	14.6	18.0	15.0
Adj EBITDA Margin (%)	20.9	20.4	21.2	22.3	22.8
Depreciation	1,622	1,769	2,279	2,432	2,584
EBIT	14,552	15,627	18,032	21,098	24,476
Other Income (Including EO Items)	3,052	2,962	3,685	4,622	5,138
Interest	531	596	333	232	136
PBT	16,928	17,239	21,184	25,488	29,477
Total Tax	3,354	2,786	4,237	5,098	5,895
Adjusted PAT	13,663	14,436	16,908	20,348	23,540
APAT Growth (%)	7.0	<i>5.7</i>	17.1	20.3	15.7
Adjusted EPS (Rs)	7.8	8.2	9.6	11.5	13.3
EPS Growth (%)	7.0	5.7	16.8	20.3	15.7

Source: Company, HDFC sec Inst Research

#### **Balance Sheet**

(Rs mn)	FY18	FY19	FY20E	FY21E	FY22E
SOURCES OF FUNDS					
Share Capital - Equity	1,762	1,762	1,767	1,767	1,767
Reserves	55,304	56,467	64,881	74,578	83,206
<b>Total Shareholders Funds</b>	57,065	58,229	66,648	76,345	84,973
Minority Interest	265	314	275	233	190
Long Term Debt	3,686	306	206	106	6
Short Term Debt	5,766	5,266	4,466	2,966	1,466
Total Debt	9,452	5,572	4,672	3,072	1,472
Net Deferred Taxes	1,091	1,091	1,091	1,091	1,091
Other Non-current Liabilities &	565	595	655	720	792
Provns TOTAL SOURCES OF FUNDS	CO 420	CF 901	72 240	91 460	00 510
APPLICATION OF FUNDS	68,438	65,801	73,340	81,460	88,518
Net Block	20,281	20,219	20,940	21,009	20,924
CWIP	522	756	767	780	795
Other Non Current Assets	490	954			
Total Non-current Assets	<b>21,293</b>		1,049 <b>22,757</b>	1,154 <b>22,943</b>	1,270 <b>22,989</b>
Inventories	•	21,929	· ·	-	-
Debtors	12,562 7,061	13,005 8,336	14,086 9,176	15,652 10,319	17,474 11,608
Other Current Assets	,	•	6,549	7,009	7,503
	4,988	6,122	•	•	
Cash & Equivalents Total Current Assets	41,112	38,029	43,984	50,931	56,714
	65,723	65,492	73,795	83,911	93,300
Creditors	17,094	19,811	21,295	23,368	25,636
Other Current Liabilities & Provns	1,484	1,809	1,917	2,026	2,134
Total Current Liabilities	18,578	21,620	23,212	25,394	27,771
Net Current Assets	47,145	43,872	50,583	58,517	65,529
TOTAL APPLICATION OF FUNDS	68,438	65,801	73,340	81,460	88,518



#### INSTITUTIONAL RESEARCH

#### **Cash Flow Statement**

Cusii i iott stateilielle					
(Rs mn)	FY18	FY19	FY20E	FY21E	FY22E
Reported PBT	16,931	17,239	21,184	25,488	29,477
Non-operating & EO Items	(2,262)	49	(39)	(42)	(42)
Interest Expenses	424	596	333	232	136
Depreciation	1,622	1,769	2,279	2,432	2,584
Working Capital Change	(2,575)	(255)	(805)	(1,039)	(1,286)
Tax Paid	(3,249)	(2,786)	(4,237)	(5,098)	(5,895)
OPERATING CASH FLOW (a)	10,890	16,611	18,715	21,973	24,974
Capex	(2,003)	(1,929)	(3,000)	(2,500)	(2,500)
Free Cash Flow (FCF)	8,887	14,682	15,715	19,473	22,474
Investments	(5,837)	4,464	(2,500)	(2,500)	(2,500)
Non-operating Income	2,437	-	-	-	-
INVESTING CASH FLOW ( b )	(5,402)	2,535	(5,500)	(5,000)	(5,000)
Debt Issuance/(Repaid)	(545)	(3,880)	(900)	(1,600)	(1,600)
Interest Expenses	(428)	(596)	(333)	(232)	(136)
FCFE	6,461	23,622	14,448	18,805	21,710
Share Capital Issuance	-	0	6	(0)	(0)
Dividend	(4,770)	(13,273)	(8,494)	(10,651)	(14,912)
Others	-	-	-	-	-
FINANCING CASH FLOW ( c )	(5,744)	(17,748)	(9,722)	(12,483)	(16,648)
NET CASH FLOW (a+b+c)	(256)	1,398	3,493	4,489	3,326
EO Items, Others	269	(17)	(39)	(42)	(42)
Closing Cash & Equivalents	3,061	4,442	7,896	12,343	15,627


Source: Company, HDFC sec Inst Research

#### **Key Ratios**

Key Ratios					
	FY18	FY19	FY20E	FY21E	FY22E
PROFITABILITY (%)					
GPM	50.5	49.5	50.2	50.6	50.7
EBITDA Margin	20.9	20.4	21.6	22.3	22.8
EBIT Margin	18.8	18.3	19.2	20.0	20.6
APAT Margin	17.7	16.9	18.0	19.3	19.8
RoE	25.9	25.0	27.1	28.5	29.2
RoIC (or Core RoCE)	47.3	50.1	53.1	59.0	65.6
RoCE	22.4	22.7	25.2	27.0	28.3
EFFICIENCY					
Tax Rate (%)	19.8	16.2	20.0	20.0	20.0
Fixed Asset Turnover (x)	2.5	2.7	2.7	2.8	3.0
Inventory (days)	59.4	55.6	54.7	54.1	53.7
Debtors (days)	33.4	35.7	35.7	35.7	35.7
Other Current Assets (days)	23.6	26.2	25.4	24.2	23.0
Payables (days)	80.8	84.7	82.7	80.7	78.7
Other Current Liab&Provns (days)	7.0	7.7	7.4	7.0	6.6
Cash Conversion Cycle (days)	28.5	25.0	25.6	26.2	27.1
Net D/E (x)	(0.6)	(0.6)	(0.6)	(0.6)	(0.7)
Interest Coverage (x)	27.4	26.2	54.2	90.8	179.5
PER SHARE DATA (Rs)					
EPS	7.8	8.2	9.6	11.5	13.3
CEPS	8.7	9.2	10.9	12.9	14.8
Dividend	6.3	4.0	5.0	7.0	9.0
Book Value	32.4	33.1	37.7	43.2	48.1
VALUATION					
P/E (x)	57.2	54.2	46.4	38.6	33.3
P/BV (x)	13.7	13.4	11.8	10.3	9.2
EV/EBITDA (x)	46.8	43.5	37.2	31.8	27.5
EV/Revenues (x)	9.8	8.9	8.1	7.1	6.3
OCF/EV (%)	1.4	2.2	2.5	2.9	3.4
FCF/EV (%)	1.2	1.9	2.1	2.6	3.0
FCFE/Mkt Cap (%)	0.8	3.0	1.8	2.4	2.8
Dividend Yield (%)	1.4	0.9	1.1	1.6	2.0
Carrier Carrier LIDEC and last Dance	1.				



#### **RECOMMENDATION HISTORY**



Date	CMP	Reco	Target
10-Oct-18	393	BUY	484
31-Oct-18	385	BUY	467
9-Jan-19	416	BUY	477
2-Feb-19	452	BUY	482
10-Apr-19	404	BUY	485
3-May-19	382	BUY	464
9-Jul-19	406	BUY	457
22-Jul-19	420	BUY	470
11-Sep-19	444	BUY	491

#### **Rating Definitions**

BUY : Where the stock is expected to deliver more than 10% returns over the next 12 month period NEUTRAL : Where the stock is expected to deliver (-)10% to 10% returns over the next 12 month period : Where the stock is expected to deliver less than (-)10% returns over the next 12 month period

# HDFC securities Institutional Equities

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013

Board: +91-22-6171 7330 www.hdfcsec.com



#### INSTITUTIONAL RESEARCH

#### Disclosure:

We, **Naveen Trivedi**, **MBA & Siddhant Chhabria**, **PGDBM**, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does not have any material conflict of interest.

#### Any holding in stock -No

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

#### Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from t date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Binkle R. Oza Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg.

No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.